Phase 2
NorthSea Therapeutics B.V. announces dosing of the first patient with icosabutate in a phase 2b dose ranging study.
Summit Therapeutics plc and collaborators will present new data analyses from the Phase 2 clinical trial of ridinilazole in patients with C. difficile infection (‘CDI’) at ID Week 2019, taking place 2-6 October 2019 in Washington, DC.
Teijin Pharma Limited announced that new topline results from a Phase II clinical trials, showing that TMX-049, which is being developed for the treatment of diabetic kidney disease in type 2 diabetes, achieved its primary endpoint for efficacy.
Ovid Therapeutics Inc. announced positive initial data from the ENDYMION trial, a Phase 2 open-label extension study of soticlestat in patients with rare developmental and epileptic encephalopathies.
Immutep Limited announces that it will receive a milestone payment from GSK of GBP 4 million related to the the first patient being dosed in GSK’s Phase II clinical trial evaluating GSK2831781 in ulcerative colitis.
Immutep Limited announces that it will receive a milestone payment from GSK of £4 million related to the first patient being dosed in GSK’s Phase II clinical trial evaluating GSK2831781 in ulcerative colitis.
It was a moderately busy week for clinical trial news. Here’s a look.
ASLAN Pharmaceuticals announced late-breaking topline data from a phase 2 study conducted in China testing varlitinib and capecitabine in second line BTC patients.
Last week was an unusually busy week for clinical trial news, with numerous companies presenting results at conferences. Here’s a look at the top stories.
Acceleron Pharma said the Phase II FSHD trial assessing the efficacy of ACE-083 did not achieve functional secondary endpoints during the study.
PRESS RELEASES